Cervical cancer vaccine: Exploring new opportunities and challenges for developing countries

被引:1
|
作者
Laskar, Ananya Ray [1 ]
Garg, Suneela [1 ]
Sodhani, Pushpa [2 ]
机构
[1] Maulana Azad Med Coll, Dept Community Med, New Delhi, India
[2] Indian Inst Cytol & Prevent Oncol ICMR, Sect 39, Noida, India
关键词
Cervarix; Gardasil; human papillomavirus vaccines; screening methods; vaccination strategy;
D O I
10.4103/1755-6783.80540
中图分类号
R188.11 [热带医学];
学科分类号
摘要
Cervical cancer is the second most common cancer in women worldwide, and the burden of the disease is disproportionately high in the developing world (>80%). With the advent of two new vaccines, "Gardasil" developed by Merck & Co. New Jersey, USA and "Cervarix" developed by GlaxoSmithKline (GSK) in Philadelphia, USA, the future holds newer promises for prevention and control of the disease. However, various regulatory and policy changes also may be required to be undertaken and the various new challenges need to be addressed.
引用
收藏
页码:54 / 56
页数:3
相关论文
共 50 条